Aktuellt
SENASTE
Redeye sees an improved outlook for Sprint Bioscience, as highlighted by its recently announced USD 277m licensing deal for oncology project Vps34. The pipeline of additional candidates for partnering bolsters our conviction. After a period of slow development for its partnered projects, the in our opinion modestly valued company is now in good shape, with its recently completed capital raise providing a solid runway until the next potential milestone payments.
LÄS MER
